



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Denosumab](#) > [Printer-friendly PDF](#)

Denosumab

Trade Name:

Xgeva

Manufacturer/Distributor:

Amgen

1-866-502-6436

Classification:

Bone resorption inhibitor

ATC Class:

M05BX04 - Denosumab

Status:

active

Notice of Compliance (yyyy/mm/dd):

2011/05/10

Date Marketed in Canada (yyyy/mm/dd):

2011/10/05

Presentation:

Injection: 120 mg/1.7 mL prefilled syringe. DIN: 02368153

Comments:

Xgeva is a RANK Ligand inhibitor intended for use in advanced cancer (reduces the risk of developing skeletal-related events in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer and other solid tumors).

Keywords: denosumab

bone neoplasms

Access:

public

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2019-08-23 02:17): <http://www.dpic.org/druglisting/denosumab-0>